105 assets in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Therapeutic assets addressing Relapsed/Refractory Diffuse Large B-Cell Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Sonrotoclax Relapsed/Refractory Diffuse Large B-Cell Lymphoma	City of Hope Medical Center	P1	C (39)
18F-granzyme B Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Olivia Newton-John Cancer Research Institute	P2	NR ()
Apg-3288 Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Ascentage Pharma Group Inc.	P1	NR ()
Gofast Cd19 Car T Cells Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Chinese PLA General Hospital	Early P1	NR ()
Mgta-456 Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Masonic Cancer Center, University of Minnesota	P2	NR ()

Showing 101 to 105 of 105 assets

PreviousPage 3 of 3Next